Advanced Medical Optics (EYE)

THIRD-QUARTER 2008 RESULTS

(SANTA ANA, CA), October 31, 2008 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] today announced financial results for the third quarter of 2008.

Third-quarter net sales rose 1.0% to $275.6 million, including a 2.7% increase related to foreign currency exchange rate effects. Third-quarter net earnings under Generally Accepted Accounting Principles (GAAP) were $7.1 million, or $0.11 per diluted share. Third-quarter results included the following pre-tax items, which combined, on an after-tax basis, to reduce net earnings per diluted share by an estimated $0.04:

In the year-ago period, the company reported a GAAP net loss of $25.9 million, or a loss of $0.43 per share, which reflected the impacts of the May 2007 eye care recall. The 2007 third-quarter results also included $5.3 million in acquisition-related charges and a $2.4 million loss on derivative instruments, which combined to increase the net loss per share by approximately $0.08.

“Our results clearly reflect the ongoing impact of deteriorating economic conditions on our refractive business, particularly in the U.S. and Europe,” said AMO Chairman and Chief Executive Officer Jim Mazzo. “However, we delivered another strong quarter across the globe in our cataract business, which is our largest at 47% of sales. While our recent multipurpose market share trends are positive, eye care sales in Japan remain below our expectations and we’ve made management and operational changes to improve our performance in future periods. Despite challenges in the quarter, we continued to make progress against key operational metrics and objectives, including reducing SG&A expense, delivering positive cash flow and taking proactive steps to reduce debt.”

“We remain focused on improving efficiencies, allocating resources to opportunities that offer the greatest return, and controlling our discretionary spending. We intend to be aggressive and disciplined in managing through this challenging economic environment while executing our long-term strategy.”

SECOND-QUARTER 2008 RESULTS

(SANTA ANA, CA), August 4, 2008 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] today announced financial results for the second quarter of 2008.

The company’s second-quarter net sales rose 22.6% to $320.5 million, including a 7.2% increase related to foreign currency exchange rate effects. Second-quarter net earnings under Generally Accepted Accounting Principles (GAAP) were $22.0 million, or $0.35 per diluted share, compared to a net loss of $166.8 million, or a loss of $2.78 per share in the same period last year. Second-quarter 2008 results included the following pre-tax items, which combined to increase net earnings per diluted share by an estimated $0.11:

“AMO’s second-quarter results showed the strength and resiliency of our global business, despite the declines in domestic refractive volumes brought on by the weakening U.S. economy,” said Jim Mazzo, AMO chairman and chief executive officer. “The value and benefit of expanding our refractive business internationally came into focus as strong refractive sales outside the U.S. helped to partially offset domestic challenges. Our cataract business took advantage of powerful new technologies and delivered solid performance domestically and internationally. And, we continued to improve the sales and profitability of our eye care franchise.”

FIRST-QUARTER 2008 RESULTS

(SANTA ANA, CA), May 1, 2008 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE] today announced financial results for the first quarter of 2008.

First-quarter net sales rose 20.7% to $303.7 million, including a 6.5% increase related to foreign currency exchange rate effects. On a pro forma basis, AMO’s first-quarter sales rose 4.4%, reflecting a comparison that includes the IntraLase performance as if this acquisition had occurred at the beginning of all periods presented.

AMO’s first-quarter net earnings under Generally Accepted Accounting Principles (GAAP) were $6.9 million, or $0.11 per diluted share, compared to $12.1 million, or $0.20 per diluted share in the same period last year. First-quarter 2008 results included the following pre-tax items, which combined to reduce net earnings per diluted share by an estimated $0.11:

“Our first-quarter results reflect our focus on delivering sustainable, profitable growth and cash flow,” said Jim Mazzo, AMO chairman and chief executive officer. “Our global refractive business achieved growth despite a soft domestic LASIK market brought on by weak economic conditions. We launched AMO’s first-ever artificial tear and prepared to introduce exciting new innovations in our refractive and cataract businesses in future quarters. Our multipurpose solution franchise continued to recover, posting sequential sales and market share gains, and helping to return our eye care business to profitability.”

SECOND-QUARTER 2007 RESULTS

(SANTA ANA, CA), August 2, 2007 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE], a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the second quarter of 2007.

The company’s second-quarter 2007 net sales rose 1.7 percent to $261.4 million. The sales increases related to the April 2007 acquisition of IntraLase Corp. and organic growth were offset by lost sales and product returns related to the May 2007 MoisturePlus recall. Foreign currency impacts increased net sales by 1.7 percent.

AMO reported a second-quarter net loss under Generally Accepted Accounting Principles (GAAP) of $166.8 million, or a loss of $2.78 per share, which included the impact of the recall. These results also included the following items, which combined to increase the net loss per share by approximately $1.98:

- more -

In the same period last year, AMO reported a GAAP net loss of $2.7 million, or a loss of $0.04 per share. A total of $52.7 million in pre-tax items reduced second-quarter 2006 results by $0.54 per share. These items were related primarily to note repurchases, rationalization and repositioning initiatives and an unrealized loss on derivative instruments.

“In the second quarter, we moved aggressively to integrate IntraLase,” said Jim Mazzo, AMO chairman, president and chief executive officer. “Our Advanced CustomVue^® technology and IntraLase^® FS laser drove laser vision correction sales to new highs, demonstrating the strategic value of this combination. In addition, our portfolio of refractive implants delivered double-digit growth on a sequential and year-over-year basis and helped fuel an 8 percent rise in intraocular lens sales. Furthermore, our eye care business moved quickly and responsibly to execute a global recall, and developed a comprehensive plan to re-enter the multipurpose contact lens care market ahead of schedule.”

FIRST-QUARTER 2007 RESULTS

(SANTA ANA, CA), April 25, 2007 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE], a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the first quarter of 2007.

The company’s net sales rose 5.6 percent to $251.7 million, including a 2.5 percent increase related to foreign currency. The company achieved growth across each of its three major business units.

AMO reported first-quarter net earnings under Generally Accepted Accounting Principles (GAAP) of $12.1 million, or $0.20 per diluted share, compared to net earnings of $2.6 million, or $0.04 per diluted share in the same period last year. These results included the following pre-tax items, which reduced net earnings per diluted share by approximately $0.03:

“In the first quarter, we continued to make meaningful progress to establish AMO as the global refractive company,” said Jim Mazzo, AMO chairman, president and chief executive officer. “Our ReZoom^® and Tecnis^® technologies led our intraocular lens growth and continued to outpace the market, our Advanced CustomVue^® technology and international expansion of the

per-procedure model drove laser vision correction sales to new highs, and we made strides to reclaim market share in our eye care business. Moreover, the WaveFront Sciences and IntraLase acquisitions demonstrate our commitment to providing refractive technologies that deliver superior outcomes, and accentuate our focus on building the refractive market, where procedures are elective and priced at their market value.”

Fourth-quarter 2006 net sales of $243.6 million represented a 3.6 percent decline compared to the same quarter last year.  The fourth-quarter net loss of $7.6 million, or a loss of $0.13 per share, was due primarily to recall-related sales declines, product returns and costs, and the tax effect of these issues. Final repositioning costs and the unrealized loss on derivative instruments increased the per share loss by $0.03.  This performance compares to net income of $2.3 million, or $0.03 per share, in the same period last year.  The fourth-quarter 2005 results were reduced by $0.37 due to the combined effect of after-tax charges of $25.8 million primarily related to rationalization and repositioning actions, as well as a tax benefit of $5.7 million for repatriation of foreign earnings and an unrealized gain on derivative instruments.

Fourth-Quarter Results

In the fourth quarter of 2005, AMO reported sales of $252.8 million, a 12.5 percent increase compared to the same quarter last year, including a 5.0 percent decrease related to foreign currency. The rise reflected the VISX acquisition, as well as growth in sales of AMO’s technologically advanced products. Fourth-quarter sales were unfavorably impacted by the rationalization of non-strategic eye care and cataract products, and lower sales in the eye care business.

AMO reported fourth-quarter 2005 net income of $2.3 million, or $0.03 per share. During the fourth quarter, the company recorded pre-tax net charges of $46.3 million, including $12.6 million for inventory provisions associated with discontinued products and $29.7 million related to severance, asset write-downs, contract terminations and other charges associated with its rationalization and repositioning strategy. The after-tax impact of the net charges, including a tax benefit of $5.7 million for repatriation of foreign earnings and an unrealized gain on derivative instruments, reduced earnings per share by $0.37. In the fourth quarter of 2004, the company reported net earnings of $10.1 million, or $0.26 per share, including approximately $11.8 million in after-tax charges related primarily to the Pfizer acquisition and associated recapitalization. These charges reduced fourth-quarter 2004 earnings per share by $0.29.

SECOND-QUARTER 2005 RESULTS

(SANTA ANA, CA), July 20, 2005 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE], today announced financial results for the second quarter of 2005.

Net revenue for the second quarter was $227.1 million, compared to $168.7 million in the same period last year. The second-quarter 2005 revenue rose 34.6 percent compared to the same period last year, including a 2.9 percent increase related to foreign currency. The growth in revenue included the May 27, 2005 acquisition of VISX, Incorporated, the acquisition of the Pfizer ophthalmic surgical business in the third quarter of 2004 and increased sales from the company’s promoted ophthalmic surgical and eye care brands.

In the second quarter, the company reported a net loss of $438.1 million, or $9.53 per share, compared to a net loss of $112.5 million, or $3.67 per share, in the same quarter one year ago. Operating performance in the second quarters of both 2005 and 2004 were heavily impacted by special charges. During the second quarter of 2005, the company recorded an after tax charge of $456.3 million, or $9.37 per share, associated with recent acquisitions, including a $451.5 million non-cash write-off for in-process research and development. The second-quarter net loss per share also excluded the effect of dilutive instruments that equated to $0.53 per share. When combined with the charges, this had the effect of reducing the company’s second-quarter earnings per share by $9.90.

The loss in the year-ago quarter was due primarily to after tax charges of approximately $121.3 million, related principally to a recapitalization. This had the effect of reducing earnings per share by $3.17. The second-quarter 2004 net loss per share also excluded the effect of dilutive instruments that equated to $0.75 per share. Together, these had the effect of reducing the company’s second-quarter 2004 earnings per share by $3.92.

“AMO’s strategy is to achieve sustained, profitable growth through innovative vision technologies that optimize the quality of life for people of all ages,” said Jim Mazzo, AMO

AMO Announces Second Quarter 2005 Results – Page 2

president and CEO. “In the second quarter, we took a major step forward in the execution of our strategy with the successful close of our acquisition of VISX, which positions AMO as the world leader in refractive surgery. We also continued to improve our global competitiveness and strengthened our foundation for future growth through increased focus on branded cataract and eye care technologies that offer clear differentiated benefits to practitioners and their patients.”

Net revenue for the first six months of 2005 was $419.6 million, compared to $319.0 million in the same period one year ago. Including a 3.3 percent positive impact of currency, the company’s revenue grew 31.5 percent, compared to the same period last year. The growth in revenue included the May 27, 2005 acquisition of VISX, the acquisition of the Pfizer ophthalmic surgical business in the third quarter of 2004 and increased sales from the company’s promoted ophthalmic surgical and eye care brands.

The company reported a net loss for the first six months of 2005 of $424.3 million, or a loss of $10.17 per share, including an after tax charge of $456.3 million, or approximately $10.27 per share, associated with recent acquisitions in the second quarter. In addition, the net loss per share for the period excluded the effect of dilutive instruments that equated to $0.62 per share. Together, these had the effect of reducing the company’s earnings per share for the first six months of 2005 by $10.89. This compared to a net loss in the first six months of 2004 of $107.8 million, or $3.59 per share, including after tax charges of approximately $121.3 million, or $3.18 per share, related primarily to a recapitalization. The net loss per share for the prior six-month period excluded the effect of dilutive instruments that equated to $0.81 per share. Together, these had the effect of reducing the company’s earnings per share for the first six months of 2004 by $3.99.

AMO reaffirmed its guidance for 2005 of revenue in the range of $920 million to $930 million and adjusted earnings per share in the range of $1.65 to $1.75. Revenue for 2006 is projected in the range of $1,020 million to $1,040 million, with 2006 adjusted earnings per share in the range of $2.20 to $2.30. Revenue for 2007 is projected in the range of $1,080 million to $1,100 million, with adjusted earnings per share at or above $2.65. AMO’s adjusted earnings guidance excludes the impact of charges related to acquisitions and debt restructurings, the impact of expensing options and the unrealized gains or losses on derivative instruments.

FIRST-QUARTER 2005 RESULTS

(SANTA ANA, CA), April 28, 2005 – Advanced Medical Optics, Inc. (AMO) [NYSE: AVO], a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the first quarter of 2005.

Net earnings for the first quarter were $13.8 million, or $0.35 per fully diluted share, up 133 percent, compared to the same period last year. The rise is attributable to increased revenue and margin expansion. The first-quarter 2005 results also included a $0.01 benefit related to currency derivatives.

Net revenue for the first quarter rose 28.1 percent, including a 3.7 percent increase related to foreign currency, to $192.5 million, compared to the first quarter of 2004. The growth in revenue reflected the acquisition of the Pfizer ophthalmic surgical business in mid 2004 and increased sales from the company’s promoted ophthalmic surgical and eye care brands.

“AMO continues to execute a focused plan for achieving sustained, profitable growth,” said Jim Mazzo, president and chief executive officer. “In the first quarter, we continued to implement our strategy to expand our leadership in the ophthalmic medical device industry. This includes building on the strategic benefits of the Pfizer ophthalmic surgical acquisition, offering products based on advanced technologies and continued implementation of a cost-efficient business model. Looking ahead, we expect to complete our acquisition of VISX in the second quarter, placing us in the leadership position of the global refractive surgical marketplace.”

AMO announced in November 2004 that it had reached an agreement with VISX, Incorporated [NYSE: EYE], the global leader in laser vision correction, to acquire the company for a combination of cash and stock. Both companies’ stockholders will vote on the transaction at special meetings to be held on May 26, 2005. Pending a successful outcome, AMO expects to

AMO Announces First Quarter 2005 Results - Page 2

close the transaction within two business days thereafter. As previously announced, AMO expects the transaction to be neutral to its 2005 adjusted earnings-per-share guidance of $1.65 to $1.75, and expects 2006 adjusted earnings per share to be in the range of $2.20 to $2.30. The company’s adjusted earnings-per-share guidance excludes any charges associated with the VISX acquisition, the impact of option expensing and the effect of currency derivatives.